


REMARKS

The specification has been amended in order to correct obvious typographical errors contained therein. No new matter has been added.

Claims 7-14 have been rejected under 35 USC 112, first and second paragraphs, for utilizing the word "derivative". In order to expedite the prosecution of the present application, Claim 7 has been amended to state that a high density lipoprotein and/or a peptide or protein of the sequence of apo A-I or apo A-II or a peptide or protein functionally homologous to the active portions of apo A-I or apo A-II in pharmaceutically acceptable form is administered to a human patient. Newly presented Claims 15 and 16 require that high density lipoprotein is administered to the patient. No new matter has been added. Claims 9 and 10 have been canceled as being redundant.

Since only formal rejections were made in the present application and the currently presented amendments have cured these formal rejections, it is respectfully submitted that the present application is now in condition for allowance. If the Examiner feels that there are any outstanding matters left to be resolved in the present application, he is respectfully requested to contact the undersigned in order that they may be dealt with.

Respectfully submitted,


Terryence F. Chapman

TFC/smd

FLYNN, THIEL, BOUTELL
& TANIS, P.C.
2026 Rambling Road
Kalamazoo, MI 49008-1631
Phone: (269) 381-1156
Fax: (269) 381-5465

Dale H. Thiel
David G. Boutell
Ronald J. Tanis
Terryence F. Chapman
Mark L. Maki
Liane L. Churney
Brian R. Tumm
Steven R. Thiel
Donald J. Wallace
Sidney B. Williams, Jr.

Reg. No. 24 323
Reg. No. 25 072
Reg. No. 22 724
Reg. No. 32 549
Reg. No. 36 589
Reg. No. 40 694
Reg. No. 36 328
Reg. No. 53 685
Reg. No. 43 977
Reg. No. 24 949

Encl: Postal Card

136.05/04